Prosecution Insights
Last updated: April 19, 2026
Application No. 18/089,265

PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM

Final Rejection §103§DP
Filed
Dec 27, 2022
Examiner
O DELL, DAVID K
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Chirogate International Inc.
OA Round
4 (Final)
58%
Grant Probability
Moderate
5-6
OA Rounds
2y 10m
To Grant
94%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allow Rate
768 granted / 1333 resolved
-2.4% vs TC avg
Strong +36% interview lift
Without
With
+35.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
43 currently pending
Career history
1376
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
32.9%
-7.1% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
28.2%
-11.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1333 resolved cases

Office Action

§103 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. Claims 16, 17, 19-25 are pending in the current application. 2. This application is a DIV of 17/408,864 08/23/2021. Response to Amendments 3. Rejections of canceled claims are withdrawn. The rejection of claims 12, 14-18 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is withdrawn based upon the amendments. The rejection of claim(s) 12, 14-15, 18 under 35 U.S.C. 102(a)(1) as being anticipated by Li GB 2495458 A is withdrawn based upon the amendments. The rejection of claim(s) 16-17, under 35 U.S.C. 103 as being unpatentable over Li GB 2495458 A is withdrawn based upon the amendments. New grounds of rejection appear below. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 4. Claim(s) 16-17, 19-25 are rejected under 35 U.S.C. 103 as being unpatentable over Li GB 2495458 A in view of Andreeta “Crystallization - Science and Technology” 2012, page 192. Li on page 7 discloses the following process: PNG media_image1.png 380 603 media_image1.png Greyscale The last section 200 ml to 100 ml of acetonitrile to 1 g of carboprost. The temperature range is 0oC -100oC which includes the claimed range. Acetonitrile is the first selection and in Example 2 on page 11, it is the crystallization solvent. With regard to the water content of acetonitrile in claim 17, this a commercial grade available and appears to be what Li used. The only difference may be the use of anhydrous acetonitrile, although this is unclear since typically anhydrous solvents are used. The acetonitrile of Li just appears to be a commercial grade with minimal water since no water is mentioned. The process is also written with the leading phrase “comprising”, which does not exclude additional steps. Since the compound was known to be recrystallized from acetonitrile, any method that places the compound in acetonitrile, by solution addition or direct dissolution would be expected to give the same or similar result. The instant claims are drawn to two recrystallizations. Melting point is depressed by contamination, and increased purity results in a higher melting range. Often contaminated solids are purified by multiple recrystallizations. It would be obvious to conduct the recrystallization in acetonitrile multiple times. Regarding the use of anhydrous acetonitrile, Andreeta on page 192 under “2.1.6 Moisture and humidity” explains: When recrystallizing from hygroscopic organic solvents, care should be taken to use only properly dried solvents (Table 3) or newly opened containers from reputable suppliers. If a crystallization process generates a metastable intermediary form, it can absorb water when exposed to moisture and change into a hydrate. Water molecules, because of their small size and multidirectional hydrogen bonding capabilities, are particularly suited to fill structural voids (Manek & Kolling, 2004). Li describes the so formed crystalline carboprost tromethamine at page 6 lines 3-15, where a maximum peak in the DSC of the claim 20, “106.4 ± 1oC”, which is the range 105.4 to 107.4 oC described by Li on line 14 as “103.97 ± 5oC”, which is the range 98.97 – 108.97oC. The peaks at the 2θ angles of the instant claim 21 are recited in lines 5-6, “6.6 ± 0.2o, 9.9 ± 0.2o, 18.5 ± 0.2o,” giving the ranges for each peak of 6.4-6.8o, 9.7-10.1o, 18.3-18.7o, respectively, which are equivalent to the first three claimed peaks. With respect to the last peak in claim 21 recited at 21.86 to 21.90, Figure 1 on page 2 of Li has this peak in the diffractogram as peak 15 giving a peak height of maximum 17.7 % of peak 1. Figure 11 is shown below on the left with instant Figure 1 on the right: PNG media_image2.png 200 400 media_image2.png Greyscale PNG media_image3.png 494 408 media_image3.png Greyscale These are the same polymorph. Looking at the Li region from 15-25 degrees θ comparing to in the instant diffractogram of figure 1 in the same region they are the same: PNG media_image4.png 500 387 media_image4.png Greyscale PNG media_image5.png 213 237 media_image5.png Greyscale Regarding the amounts of impurities in claims 23-25, since it is a crystalline solid that does not show evidence of the other isomers in the diffractogram this is an inherent feature of the pure material. The melting point is sharp and the IR in Li does not show peaks for the trans isomers, which will appear. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. 8. Claim 16, 17, 19-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 16-17 of copending Application No. 17/408,864 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because while the instant claims embrace an additional recrystallization, contaminated solids are purified by multiple recrystallizations. Melting point is depressed by contamination, and increased purity results in a higher melting range. It would be obvious to conduct the recrystallization in acetonitrile multiple times. The materials have all the properties of claims 20-25. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion 9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID K O'DELL whose telephone number is (571)272-9071. The examiner can normally be reached on Monday - Friday 9:30 - 7:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached on 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAVID K O'DELL/Primary Examiner, Art Unit 1621 1 This figure is also available in Li’s Canadian filing, CA 2805959, and the Chinese PCT filing, WO20120100089 which have clearer images.
Read full office action

Prosecution Timeline

Dec 27, 2022
Application Filed
Dec 02, 2023
Non-Final Rejection — §103, §DP
Jun 07, 2024
Response Filed
Jul 02, 2024
Final Rejection — §103, §DP
Dec 05, 2024
Request for Continued Examination
Dec 09, 2024
Response after Non-Final Action
Jan 28, 2025
Non-Final Rejection — §103, §DP
Aug 04, 2025
Response Filed
Oct 30, 2025
Final Rejection — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600698
KINASE INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Patent 12595241
METHOD OF PRODUCING PERFLUORO(2,4-DIMETHYL-2-FLUOROFORMYL-1,3-DIOXOLANE)
2y 5m to grant Granted Apr 07, 2026
Patent 12583845
COMPOSITIONS AND METHODS FOR TREATING DISEASES, DISORDERS AND CONDITIONS INVOLVING TRINUCLEOTIDE REPEATS
2y 5m to grant Granted Mar 24, 2026
Patent 12565468
PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM
2y 5m to grant Granted Mar 03, 2026
Patent 12551490
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
58%
Grant Probability
94%
With Interview (+35.9%)
2y 10m
Median Time to Grant
High
PTA Risk
Based on 1333 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month